

Prostate Cancer Factsheet: Insights & Key Developments

Key Insights on Prostate Cancer
Care and Infrastructure

Core Pillars:

1. Infrastructure
2. Treatment Access, Research Funding and Awareness Campaigns
3. Survival Rates, Early Detection and Palliative Care
4. Utilization of Biomarkers
5. Clinical Guidelines
6. Reimbursement
7. Prostate Cancer Screening

Prostate cancer remains one of the most prevalent cancers worldwide, affecting millions of individuals each year. Despite advancements in diagnostics, treatment, and awareness, disparities in access to care, molecular testing, and specialized centers persist.


This factsheet provides a comprehensive overview of key pillars shaping Prostate cancer care, including specialized infrastructure, treatment accessibility, research funding, early detection, and palliative care.

- **Incidence share:** Prostate cancer is the most commonly diagnosed male cancer in Spain.
- **Incidence rate:** Approximately 74 per 100,000 men per year.
- **Total new cases (2022):** Around 30,000 men.
- **Daily diagnoses (2022):** Roughly 82 men per day.
- **Deaths (2022):** About 5,500–6,000 men.
- **5-year survival rate:** Estimated ≈ 85–90%.
- **Most affected age group:** Primarily men aged 65 and older.
- **Screening participation:** PSA testing available but no national organized screening; participation varies.

Spain



Infrastructure



Strengths

- Spain has a robust public healthcare system (SNS) with specialized oncology units and comprehensive cancer centers such as CNIO (National Cancer Research Centre).
- Availability of robotic surgery (Da Vinci), radiotherapy, and nuclear imaging in major urban hospitals.

Weakness


- Infrastructure disparities exist between autonomous regions, with rural provinces having less access to advanced diagnostics and treatments.
- Some fragmentation in care pathways for advanced prostate cancer

Opportunity

- Strengthen regional cancer networks and use digital tools to bridge gaps between urban and rural care.
- Invest in capacity-building for molecular diagnostics in regional hospitals.

Threats


- Economic pressures on the healthcare budget can affect equitable infrastructure expansion.
- Dependency on public funding cycles may delay technology updates



Country	Specialized Centers	Genetic & Molecular Testing Infrastructure
South Africa		
Kenya		
Nigeria		
Egypt		
Morocco		
Algeria		
Ethiopia		
India		
Japan		
South Korea		
China		
Thailand		
Singapore		
United Kingdom		
Germany		
France		
Netherlands		
Sweden		
Italy		
Spain		
Poland		
Mexico		
Brazil		
Argentina		
Chile		
Colombia		
United States		
Canada		
Australia		
New Zealand		
Greece		
Rwanda		
Uganda		
Serbia		
Saudi Arabia		
UAE		
Syria		
Indonesia		
Vietnam		
Philippines		
Russia		
Malaysia		

Spain

Treatment Access, Research Funding and Awareness Campaigns



Strengths

- Spain participates in multiple European cancer research initiatives, with government and EU support.
- Treatments for prostate cancer – including surgery, radiotherapy, hormonal therapy, and chemotherapy – are covered under universal healthcare.

Weakness

- Limited dedicated awareness campaigns focused on prostate cancer compared to breast or colorectal cancer.
- Genomic research funding still relatively modest compared to northern European countries.

Opportunity

- Launch targeted awareness drives for men 50+ in collaboration with NGOs.
- Boost public-private collaboration in biomarker trials and genomics R&D

Threats


- Prostate cancer can be under-prioritized due to higher perceived burden from other cancers.
- Fragmentation across 17 autonomous communities may lead to inconsistent resource allocation.

5. Strong healthcare infrastructure with comprehensive treatment access, high research funding, and nationwide awareness campaigns. Patients have access to advanced therapies, clinical trials, and widespread early detection programs.
4. Well-developed system with good treatment availability, strong research funding, and effective but regionally focused awareness campaigns. Some disparities may exist in rural areas or between public and private sectors.
3. Moderate development, with specialized treatments available in major hospitals, research funding concentrated on specific cancers, and occasional but limited awareness efforts. Healthcare access may be restricted by cost or geography.
2. Limited system where cancer treatment is available only in select urban centers, research funding is minimal or sporadic, and awareness campaigns are rare or underfunded. Patients often face long wait times or financial barriers.
1. Poor infrastructure with severe barriers to treatment, little to no research funding, and lack of structured awareness campaigns. Cancer care is largely inaccessible, with many patients relying on out-of-pocket expenses or external aid.

Country	Treatment Access	Research Funding	Awareness Campaigns
South Africa			
Kenya			
Nigeria			
Egypt			
Morocco			
Algeria			
Ethiopia			
India			
Japan			
South Korea			
China			
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland			
Mexico			
Brazil			
Argentina			
Chile			
Colombia			
United States			
Canada			
Australia			
New Zealand			
Greece			
Rwanda			
Uganda			
Serbia			
Saudi Arabia			
UAE			
Syria			
Indonesia			
Vietnam			
Philippines			
Russia			
Malaysia			

Spain

Survival Rates, Early Detection and Palliative Care



Strengths

- Spain has a high prostate cancer survival rate (~90%), owing to early detection and access to treatment.
- Widespread use of PSA screening in clinical practice and high awareness among urologists.

Weakness

- Late-stage patients may face delays in accessing palliative care services, especially outside major cities.
- Lack of structured survivorship programs post-treatment.

Opportunity

- Strengthen community-level palliative and psycho-oncological support.
- Implement structured survivorship and follow-up clinics for localized and metastatic cases.

Threats

- Aging male population may increase prostate cancer incidence and overwhelm current palliative systems.
- Regional inequalities in early detection programs.



5. High survival rates, strong early detection programs, and well-established palliative care services. Patients have access to timely diagnosis, advanced treatments, and comprehensive end-of-life care.



4. Good survival rates, effective early detection efforts, and accessible but regionally limited palliative care. Some disparities may exist in rural areas or for specific cancer types.






























































































































3. Moderate survival rates, early detection available but not widespread, and palliative care services mainly in urban centers. Some patients experience delays in diagnosis or limited end-of-life care.



2. Low survival rates, early detection efforts are inconsistent or underfunded, and palliative care is minimal or only available in select hospitals. Cancer patients face significant access barriers.




1. Very low survival rates, poor early detection infrastructure, and almost no palliative care services. Many patients are diagnosed late and lack proper support for pain management and end-of-life care.

Country	Survival Rates	Early Detection	Palliative Care
South Africa			
Kenya			
Nigeria			
Egypt			
Morocco			
Algeria			
Ethiopia			
India			
Japan			
South Korea			
China			
Thailand			
Singapore			
United Kingdom			
Germany			
France			
Netherlands			
Sweden			
Italy			
Spain			
Poland			
Mexico			
Brazil			
Argentina			
Chile			
Colombia			
United States			
Canada			
Australia			
New Zealand			
Greece			
Rwanda			
Uganda			
Serbia			
Saudi Arabia			
UAE			
Syria			
Indonesia			
Vietnam			
Philippines			
Russia			
Malaysia			

Spain

Utilization of Biomarkers



Strengths

- PSA is routinely used in public and private clinical practice for detection and monitoring.
- BRCA1/2 testing is available, especially in academic hospitals and in patients with family history.

Opportunity

- Integrate multigene testing panels (BRCA, ATM, CHEK2, PTEN) into treatment planning, particularly for mCRPC.
- Participate in cross-European consortia for biomarker validation.


Weakness

- PTEN and TMRSS2-ERG are not widely used in routine clinical decision-making.
- Low physician-patient discussion rate on genetic biomarkers unless hereditary syndromes are suspected.

Threats

- Inconsistent reimbursement policies across regions for biomarker testing.
- Over-reliance on PSA may lead to overdiagnosis without stratified care pathways.

- Moderate utilization, often restricted to major hospitals or private healthcare settings. Some patients may not receive biomarker testing due to cost or limited availability in public healthcare systems.
- Biomarker testing is available but underutilized, with significant barriers such as high costs, lack of awareness, or limited infrastructure. Many patients may not receive recommended biomarker assessments.
- Biomarker testing is rarely performed, often due to lack of infrastructure, awareness, or financial barriers. Patients typically do not receive targeted therapies based on biomarker status.



Spain



Clinical Guidelines

Strengths

- Spain follows European Association of Urology (EAU) and ESMO guidelines, with national adaptation.
- Active use of multidisciplinary tumor boards for treatment planning in tertiary centers.

Weakness



- National guidelines have limited incorporation of molecular biomarkers like PTEN and TMRSS2-ERG.
- Regional variation in guideline implementation fidelity.

Opportunity

- Update national protocols to incorporate genomic testing for advanced disease.
- Create Spain-specific clinical pathways that reflect local epidemiology and biomarker profiles.

Threats

- Policy fragmentation across regions can delay uniform guideline execution.
- Rapid biomarker innovation may outpace national adoption capacity.




	Very High	High	Medium	Low	Very Low
Clinical Guideline Implementation	○	×	×	×	×
Feasibility of Integration	○	×	×	×	×
Adoption of International Guidelines	○	×	×	×	×
Engagement with Updates	×	×	○	×	×
ESMO Guidelines Implementation	○	×	×	×	×

Spain



Reimbursement



Spain

Prostate Cancer Screening

Strengths

- PSA testing is widely available and offered opportunistically through urology and general practice.
- Executive health checks often include PSA as a standard marker for men over 50.

Weakness

- No organized national screening program for prostate cancer.
- Follow-up after elevated PSA may lack standardization, leading to variability in care.

Opportunity

- Implement risk-stratified screening strategies for men with familial or genetic risk (BRCA carriers).
- Utilize electronic health records for targeted outreach and reminders.

Threats

- Public perception of PSA may be shaped by controversies around overdiagnosis.
- Cultural hesitation among older men to seek regular urologic checkups.

Country	Prostate Cancer Screening
United States	Annual LDCT (50-80 years, high-risk smokers)
United Kingdom	LDCT for high-risk individuals (55-74 years)
Canada	LDCT for high-risk individuals (55-74 years)
Australia	No national program, high-risk groups advised LDCT
Germany	No national program, under evaluation
France	No national LDCT screening
Netherlands	Participating in European screening studies
Sweden	No national LDCT screening
Italy	Regional pilot LDCT screening
Spain	No national LDCT program
Poland	No national program
Japan	No national LDCT program
South Korea	LDCT for high-risk individuals (50-74 years)
China	No national LDCT program
India	No national LDCT program
Singapore	No national LDCT program
Saudi Arabia	No national LDCT program; some hospital-based opportunistic screening
UAE	No national LDCT program; early-stage pilot studies ongoing in select hospitals
Syria	No national LDCT program; screening not prioritized due to conflict
Malaysia	No program; high-risk CT pilots

Country	Prostate Cancer Screening
Thailand	No national LDCT program
South Africa	No national LDCT program
Kenya	No national LDCT program
Nigeria	No national LDCT program
Egypt	No national LDCT program
Morocco	No national LDCT program
Algeria	No national LDCT program
Ethiopia	No national LDCT program
Mexico	No national LDCT program
Brazil	No national LDCT program
Argentina	No national LDCT program
Chile	No national LDCT program
Colombia	No national LDCT program
New Zealand	No national LDCT program
Greece	No national LDCT program
Rwanda	No national LDCT program
Uganda	No national LDCT program
Serbia	No national LDCT program
Indonesia	No national LDCT program; opportunistic screening in private sector
Vietnam	No national LDCT program; early pilot screening studies in Hanoi and Ho Chi Minh
Philippines	No national LDCT program; feasibility and awareness programs under discussion
Russia	No formal national LDCT program; regional pilot screening programs in large cities